Preparation of 6-[18F]fluoro-L-DOPA and its biodistribution in normal and unilateral PD model rats

Preparation of 6-[¹⁸F]fluoro-L-DOPA and its biodistribution in normal and unilateral PD model rats

ZHANG Lan，

TANG Gang-Hua，

WANG Yong-Xian，

YIN Duan-Zhi

Nuclear Science and Techniques

Vol.13, No.4

pp.244-250

Published in print 01 Nov 2002

CLC：O615.3

33500

No-carrier-added 6-[¹⁸F] fluoro-L-DOPA (6-FDOPA) was synthesized via a multistep procedure from a commercial available precursor, 6-nitroveratraldehyde, The total synthesis time was 75min, with a radiochemical yield of (10±3)%, high radiochemical purity (>99%) and high enantiomeric purity (>95%) The biodistributions of 6-FDOPA in normal and unilateral PD model rats were measured. The results from normal rats showed the expected high concentration of radioactivity in striatum and low distributions in cerebrum, cortex and cerebellum. The ratio of the radioactivity in striatum to cerebellum reached a peak value (5.9) at 60 min. In unilateral PD model rats, whose substania nigra of the right side had been damaged by pre-treated with 6-OHDA, the radioactive concentration in striatum of the damaged side was significantly lower than that of the undamaged side or that of both sides in striatum of control groups.

6-[18F]fluoro-L-DOPABiodistributionRatsUnilateral PD model

References

Luxen A, Guillaume M, Melega W P et al. Nucl Med Biol, 1992, 19: 149-158

Dolle F, Denphel S, Hinnen S et al. J Labelled Compd Radiopharm, 1998, XLI: 105-114

Lemaire C, Guillaume M, Cantineau R et al. J Nucl Med, 1990, 31: 1247-1251

Lemaire C, Damhaut P, Plenevaux A et al. J Nucl Med, 1994, 35: 1996-2002

Najafi A.

Nucl Med Biol, 1995, 22: 395-397

Landais P, Bonnefoi F, Kudlyk V et al. J Labelled Compd Radiopharm, 1995, 37: 647-651

Lemaire C, Guillouet S, Brihaye C et al. J Labelled Compd Radiopharm, 1999, 42(suppl 1): s113-s115

Guillouet S, Lemaire C, Bonmarchand G et al. J Labelled Compd Radiopharm. 2001. 44(suppl): s868-s870

Firnau G, Garnett E S, Chan P K H et al. J Pharm Pharmacol, 1976, 28: 584-585

Home M K, Cheng C H, Wooten G F.

Pharmacology, 1984, 28: 12-26

Javoy-Agid F, Agid Y.

Neurology, 1980, 30(12): 1326-1330

Lindvall O, Bjorklund A.

Acta Physiol Scand Suppl. 1974, 412: 1-48

Anden N E, Carlsson A, Haggendal J.

Annu Rev Pharmacol, 1969, 9: 119-134

Garnett E S, Firnau G, Nahmias C.

Nature, 1983, 305(8): 137-138

Corey E J, Xu F, Noc M C.

J Am Chem Soc, 1997, 119: 12414-12415

Keinan E, Perez D, Sahai M et al. J Org Chem, 1990, 55: 2927-2938

Hoffman J M, Melega W P, Hawk T C et al. J Nucl Med, 1992, 33: 1472-1477